From July 4th to 5th, the "2024 International Pharmaceutical Service Industry Innovation and Development Conference and the 9th China Pharmaceutical R&D and Innovation Summit" was grandly opened at the Xiong'an Convention and Exhibition Center in China. Among them, the much-watched "2024 China Traditional Chinese Medicine R&D Strength Ranking" was officially announced. Jiangsu Kangyuan Pharmaceutical Co., Ltd. once again won the top position of the "Chinese Medicine List", which shows that the R&D strength and innovation level of Kangyuan Pharmaceutical have been affirmed by the expert committee and fully affirmed and recognized by the industry.
This summit focuses on the direction of "new drug R&D and clinical trials", invites a number of academicians to attend, brings together hundreds of industry experts from government, industry, medicine, academia, research and capital, and faces professionals in the R&D and clinical aspects of the pharmaceutical industry to jointly explore the development trend of innovative drugs, the innovation of the biomedical industry chain, cutting-edge technologies, clinical trials, and the exploration of the core value of commercialization of innovative drug enterprises, so as to effectively promote the creation of a pharmaceutical innovation ecosystem and new quality productivity, and accelerate the high-quality development of China's innovative drug industry.
The "2024 China Traditional Chinese Medicine R&D Strength Ranking" and other lists are calculated by the Pharmaceutical Intelligence Network, the Expert Committee of the Drug R&D Strength Ranking, and the Organizing Committee of the 2024 China Pharmaceutical R&D Innovation Summit according to the six parts of the company's domestic drug acceptance and approval score, pharmaceutical company's R&D investment fund score, domestic drug clinical trial score, foreign drug R&D score, patent score and the company's historical drug R&D ranking score (2023).
As a cultural treasure with a history of thousands of years, traditional Chinese medicine has played an irreplaceable role in the prosperity and development of Chinese civilization. In recent years, the traditional Chinese medicine industry has been highly valued by the state, the top-level design of traditional Chinese medicine development has been continuously improved, the policy environment has been continuously optimized, and the support has been continuously increased, ushering in new opportunities for high-quality development of the traditional Chinese medicine industry.
As a leading enterprise in the R&D and innovation of traditional Chinese medicine, Kangyuan Pharmaceutical adheres to the innovative spirit of "Boss Jingyi, Magnolia Yuanzhi", has been immersed in scientific and technological innovation of traditional Chinese medicine for 30 years, is committed to the standardization, intelligence and internationalization of traditional Chinese medicine for high-level scientific and technological self-reliance and self-improvement, and is guided by the theory of traditional Chinese medicine, focusing on the advantageous fields of traditional Chinese medicine, using cutting-edge advanced technology of modern drug research and development, and developing innovative traditional Chinese medicine drugs with clearer material basis, clearer mechanism, more refined preparations and more precise indications, and promoting industrial innovation with scientific and technological innovation. Promote the high-quality development of traditional Chinese medicine and accelerate the formation of new quality productivity in the traditional Chinese medicine industry.
With the National Key Laboratory of Process Control and Intelligent Manufacturing Technology of Traditional Chinese Medicine and the National and Local Joint Engineering Research Center for Intelligent Manufacturing Technology of Traditional Chinese Medicine as the core, Kangyuan Pharmaceutical Co., Ltd. integrates scientific research platforms at all levels such as national postdoctoral research workstations and school-enterprise co-construction laboratories to form a multi-level and three-dimensional comprehensive scientific and technological innovation carrier covering "innovative Chinese medicine discovery, new drug research and development, intelligent manufacturing, and post-marketing re-evaluation", and has successively undertaken more than 40 national science and technology projects such as the 973 Program, the 863 Program, and major new drug creation. More than 600 invention patents have been authorized, and it has been selected into the first batch of "R&D Institutions with International Influence (Level 1)" cultivation library in Jiangsu Province.
For the first time, the company proposed the decoding theory of the Chinese patent medicine system with functional substances as the core, which provides a theoretical basis for the "what to control" and "how to control" the complex component system of the traditional Chinese medicine pharmaceutical process. Innovate the discovery technology of functional components of proprietary Chinese medicines, and develop the first innovative combination of functional components for ischemic stroke targeting PAF receptors; The first whole-process quality control system with functional ingredients as the core realizes the quality control of "whole-process dynamic whole" and significantly improves product uniformity; It pioneered the intelligent manufacturing technology of Chinese patent medicine, breaking through the bottleneck of big data collection, analysis and application in the pharmaceutical industry; The technological achievements have won 1 second prize of the National Technological Invention Award, 3 second prizes of the National Science and Technology Progress Award, and 2 China Patent Gold Awards, continuously injecting technological momentum into the development of new productivity in the traditional Chinese medicine industry.
In the future, Kangyuan Pharmaceutical will continue to adhere to innovation-driven development, continuously improve its independent innovation capabilities, continue to promote the high-quality development of the enterprise, and develop innovative drugs with clinical advantages and characteristics; Adhere to an open mind, continuously strengthen cooperation and exchanges with the industry, build consensus, and better play a leading role in innovation in the Chinese medicine industry.